CoChat
Sign Up
Cited by 746

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Mesenchymal stem cell: An efficient mass producer of exosomes for drug delivery

Yeo, Ronne Wee Yeh, Lai, Ruenn Chai, Zhang, Bin, Tan, Soon Sim, Yin, Yijun, Teh, Bao Ju, Lim, Sai Kiang·2013·Advanced Drug Delivery Reviews
DOI 10.1016/j.addr.2012.07.001
Open this paper in CoChat — free account

Abstract

Advances in biomedical research have generated an unprecedented number of potential targets for therapeutic intervention to treat disease or delay disease progression. Unfortunately, many of these targets are not druggable as they are intracellular, present in many cell types, poorly soluble or rapidly inactivated. Although synthetic drug vehicles have successfully circumvented many of these problems, natural particulates such as exosomes that intrinsically possess many attributes of a drug delivery vehicle are highly attractive as potentially better alternatives. Of the cell types known to produce exosomes, the readily available proliferative, immunosuppressive and clinically tested human mesenchymal stem cell (MSC) is the most prolific producer. Its exosomes are therapeutic in animal model of disease and exhibit immunosuppressive activity. The quality and quantity of exosome production is not compromised by immortalization to create a permanent MSC cell line. Therefore, MSC is well suited for mass production of exosomes that are ideal for drug delivery.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.addr.2012.07.001

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 110

  1. Symon, 1999, Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes, Cancer, 86, 72, 10.1002/(SICI)1097-0142(19990701)86:1<72::AID-CNCR12>3.0.CO;2-1 · DOI
  2. Perez, 2002, Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: the Cancer Research Network, Inc., experience, Cancer Invest., 20, 22, 10.1081/CNV-120014883 · DOI
  3. O'Shaughnessy, 2003, Pegylated liposomal doxorubicin in the treatment of breast cancer, Clin. Breast Cancer, 4, 318, 10.3816/CBC.2003.n.037 · DOI
  4. Goncalves, 2003, Phase I study of pegylated liposomal doxorubicin (Caelyx) in combination with carboplatin in patients with advanced solid tumors, Anticancer Res., 23, 3543
  5. Harrington, 2001, Phase II study of pegylated liposomal doxorubicin (Caelyx) as induction chemotherapy for patients with squamous cell cancer of the head and neck, Eur. J. Cancer, 37, 2015, 10.1016/S0959-8049(01)00216-7 · DOI
  6. Schmidinger, 2001, Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma, Br. J. Cancer, 85, 1850, 10.1054/bjoc.2001.2149 · DOI
  7. Schwonzen, 2000, Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer, Anticancer Drugs, 11, 681, 10.1097/00001813-200010000-00002 · DOI
  8. Seiden, 2004, A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer, Gynecol. Oncol., 93, 229, 10.1016/j.ygyno.2003.12.037 · DOI
  9. Skubitz, 2003, Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma, Cancer Invest., 21, 167, 10.1081/CNV-120016412 · DOI
  10. Wollina, 2003, Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma, Cancer, 98, 993, 10.1002/cncr.11593 · DOI
  11. Johnston, 2001, Caelyx: phase II studies in ovarian cancer, Eur. J. Cancer, 37, S8, 10.1016/S0959-8049(01)00329-X · DOI
  12. Sundar, 2003, Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study, Clin. Infect. Dis., 37, 800, 10.1086/377542 · DOI
  13. Grant, 2004, A novel liposomal bupivacaine formulation to produce ultralong-acting analgesia, Anesthesiology, 101, 133, 10.1097/00000542-200407000-00021 · DOI
  14. Yoo, 2011, Bio-inspired, bioengineered and biomimetic drug delivery carriers, Nat. Rev. Drug Discov., 10, 521, 10.1038/nrd3499 · DOI
  15. Simons, 2009, Exosomes — vesicular carriers for intercellular communication, Curr. Opin. Cell Biol., 21, 575, 10.1016/j.ceb.2009.03.007 · DOI
  16. van den Boorn, 2011, SiRNA delivery with exosome nanoparticles, Nat. Biotechnol., 29, 325, 10.1038/nbt.1830 · DOI · Paper page
  17. Lakhal, 2011, Exosome nanotechnology: an emerging paradigm shift in drug delivery, Bioessays, 33, 737, 10.1002/bies.201100076 · DOI · Paper page
  18. Pan, 1983, Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor, Cell, 33, 967, 10.1016/0092-8674(83)90040-5 · DOI
  19. Fevrier, 2004, Exosomes: endosomal-derived vesicles shipping extracellular messages, Curr. Opin. Cell Biol., 16, 415, 10.1016/j.ceb.2004.06.003 · DOI · Paper page
  20. Wubbolts, 2003, Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation, J. Biol. Chem., 278, 10,963, 10.1074/jbc.M207550200 · DOI
  21. de Gassart, 2003, Lipid raft-associated protein sorting in exosomes, Blood, 102, 4336, 10.1182/blood-2003-03-0871 · DOI
  22. Escola, 1998, Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes, J. Biol. Chem., 273, 20,121, 10.1074/jbc.273.32.20121 · DOI · Paper page
  23. Zitvogel, 1998, Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes, Nat. Med., 4, 594, 10.1038/nm0598-594 · DOI
  24. Pegtel, 2010, Functional delivery of viral miRNAs via exosomes, Proc. Natl. Acad. Sci. U. S. A., 107, 6328, 10.1073/pnas.0914843107 · DOI
  25. Lachenal, 2011, Release of exosomes from differentiated neurons and its regulation by synaptic glutamatergic activity, Mol. Cell. Neurosci., 46, 409, 10.1016/j.mcn.2010.11.004 · DOI
  26. Bakhti, 2011, Inhibition of myelin membrane sheath formation by oligodendrocyte-derived exosome-like vesicles, J. Biol. Chem., 286, 787, 10.1074/jbc.M110.190009 · DOI
  27. Vrijsen, 2010, Cardiomyocyte progenitor cell-derived exosomes stimulate migration of endothelial cells, J. Cell. Mol. Med., 14, 1064
  28. Miyado, 2008, The fusing ability of sperm is bestowed by CD9-containing vesicles released from eggs in mice, Proc. Natl. Acad. Sci. U. S. A., 105, 12,921, 10.1073/pnas.0710608105 · DOI
  29. Lai, 2010, Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury, Stem Cell Res., 4, 214, 10.1016/j.scr.2009.12.003 · DOI · Paper page
  30. Bruno, 2009, Mesenchymal stem cell-derived microvesicles protect against acute tubular injury, J. Am. Soc. Nephrol., 20, 1053, 10.1681/ASN.2008070798 · DOI
  31. Fevrier, 2004, Cells release prions in association with exosomes, Proc. Natl. Acad. Sci. U. S. A., 101, 9683, 10.1073/pnas.0308413101 · DOI
  32. Lenassi, 2010, HIV Nef is secreted in exosomes and triggers apoptosis in bystander CD4+ T cells, Traffic, 11, 110, 10.1111/j.1600-0854.2009.01006.x · DOI
  33. Porto-Carreiro, 2005, Prions and exosomes: from PrPc trafficking to PrPsc propagation, Blood Cells Mol. Dis., 35, 143, 10.1016/j.bcmd.2005.06.013 · DOI
  34. Vallhov, 2011, Exosomes containing glycoprotein 350 released by EBV-transformed B cells selectively target B cells through CD21 and block EBV infection in vitro, J. Immunol., 186, 73, 10.4049/jimmunol.1001145 · DOI
  35. Bhatnagar, 2007, Exosomes released from infected macrophages contain Mycobacterium avium glycopeptidolipids and are proinflammatory, J. Biol. Chem., 282, 25,779, 10.1074/jbc.M702277200 · DOI
  36. Hao, 2006, Epigenetic transfer of metastatic activity by uptake of highly metastatic B16 melanoma cell-released exosomes, Exp. Oncol., 28, 126
  37. Valenti, 2006, Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-β-mediated suppressive activity on T lymphocytes, Cancer Res., 66, 9290, 10.1158/0008-5472.CAN-06-1819 · DOI · Paper page
  38. Camussi, 2011, Exosome/microvesicle-mediated epigenetic reprogramming of cells, Am. J. Cancer Res., 1, 98
  39. Alvarez-Erviti, 2011, Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes, Nat. Biotechnol., 29, 341, 10.1038/nbt.1807 · DOI · Paper page
  40. Simpson, 2008, Proteomic profiling of exosomes: current perspectives, Proteomics, 8, 4083, 10.1002/pmic.200800109 · DOI
  41. Thery, 2002, Indirect activation of naive CD4+ T cells by dendritic cell-derived exosomes, Nat. Immunol., 3, 1156, 10.1038/ni854 · DOI
  42. Andre, 2004, Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells, J. Immunol., 172, 2126, 10.4049/jimmunol.172.4.2126 · DOI · Paper page
  43. Hood, 2011, Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis, Cancer Res., 71, 3792, 10.1158/0008-5472.CAN-10-4455 · DOI
  44. Peters, 1989, Molecules relevant for T cell-target cell interaction are present in cytolytic granules of human T lymphocytes, Eur. J. Immunol., 19, 1469, 10.1002/eji.1830190819 · DOI
  45. Heijnen, 1999, Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and α-granules, Blood, 94, 3791, 10.1182/blood.V94.11.3791 · DOI
  46. Wolfers, 2001, Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming, Nat. Med., 7, 297, 10.1038/85438 · DOI
  47. Sokolova, 2011, Characterisation of exosomes derived from human cells by nanoparticle tracking analysis and scanning electron microscopy, Colloids Surf. B Biointerfaces, 87, 146, 10.1016/j.colsurfb.2011.05.013 · DOI
  48. Clayton, 2011, Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production, J. Immunol., 187, 676, 10.4049/jimmunol.1003884 · DOI · Paper page
  49. Sullivan, 2005, Role of exosomes in sperm maturation during the transit along the male reproductive tract, Blood Cells Mol. Dis., 35, 1, 10.1016/j.bcmd.2005.03.005 · DOI
  50. Mathivanan, 2010, Exosomes: extracellular organelles important in intercellular communication, J. Proteomics, 73, 1907, 10.1016/j.jprot.2010.06.006 · DOI
  51. Thery, 2002, Exosomes: composition, biogenesis and function, Nat. Rev. Immunol., 2, 569, 10.1038/nri855 · DOI
  52. Stoorvogel, 2002, The biogenesis and functions of exosomes, Traffic, 3, 321, 10.1034/j.1600-0854.2002.30502.x · DOI
  53. Pisitkun, 2004, Identification and proteomic profiling of exosomes in human urine, Proc. Natl. Acad. Sci. U. S. A., 101, 13,368, 10.1073/pnas.0403453101 · DOI
  54. Andre, 2002, Malignant effusions and immunogenic tumour-derived exosomes, Lancet, 360, 295, 10.1016/S0140-6736(02)09552-1 · DOI
  55. Dai, 2005, More efficient induction of HLA-A*0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells, Clin. Cancer Res., 11, 7554, 10.1158/1078-0432.CCR-05-0810 · DOI
  56. Clayton, 2007, Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2, Cancer Res., 67, 7458, 10.1158/0008-5472.CAN-06-3456 · DOI
  57. Taylor, 2008, MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer, Gynecol. Oncol., 110, 13, 10.1016/j.ygyno.2008.04.033 · DOI
  58. Mathivanan, 2012, ExoCarta 2012: database of exosomal proteins, RNA and lipids, Nucleic Acids Res., 40, D1241, 10.1093/nar/gkr828 · DOI
  59. Hunter, 2008, Detection of microRNA expression in human peripheral blood microvesicles, PLoS One, 3, 10.1371/journal.pone.0003694 · DOI
  60. Rabinowits, 2009, Exosomal microRNA: a diagnostic marker for lung cancer, Clin. Lung Cancer, 10, 42, 10.3816/CLC.2009.n.006 · DOI
  61. Kosaka, 2010, Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis, Cancer Sci., 101, 2087, 10.1111/j.1349-7006.2010.01650.x · DOI · Paper page
  62. Kern, 2006, Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue, Stem Cells, 24, 1294, 10.1634/stemcells.2005-0342 · DOI · Paper page
  63. Banas, 2007, Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes, Hepatology, 46, 219, 10.1002/hep.21704 · DOI · Paper page
  64. Arai, 2002, Mesenchymal stem cells in perichondrium express activated leukocyte cell adhesion molecule and participate in bone marrow formation, J. Exp. Med., 195, 1549, 10.1084/jem.20011700 · DOI
  65. In 't Anker, 2003, Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential, Haematologica, 88, 845
  66. Young, 2001, Human reserve pluripotent mesenchymal stem cells are present in the connective tissues of skeletal muscle and dermis derived from fetal, adult, and geriatric donors, Anat. Rec., 264, 51, 10.1002/ar.1128 · DOI
  67. Roubelakis, 2007, Molecular and proteomic characterization of human mesenchymal stem cells derived from amniotic fluid: comparison to bone marrow mesenchymal stem cells, Stem Cells Dev., 16, 931, 10.1089/scd.2007.0036 · DOI
  68. Fukuchi, 2004, Human placenta-derived cells have mesenchymal stem/progenitor cell potential, Stem Cells, 22, 649, 10.1634/stemcells.22-5-649 · DOI
  69. Miao, 2006, Isolation of mesenchymal stem cells from human placenta: comparison with human bone marrow mesenchymal stem cells, Cell Biol. Int., 30, 681, 10.1016/j.cellbi.2006.03.009 · DOI
  70. Brooke, 2007, Therapeutic applications of mesenchymal stromal cells, Semin. Cell Dev. Biol., 18, 846, 10.1016/j.semcdb.2007.09.012 · DOI
  71. Huang, 2009, Mesenchymal stem cells derived from dental tissues vs. those from other sources: their biology and role in Regenerative Medicine, J. Dent. Res., 88, 792, 10.1177/0022034509340867 · DOI
  72. Lai, 2010, Derivation and characterization of human fetal MSCs: an alternative cell source for large-scale production of cardioprotective microparticles, J. Mol. Cell. Cardiol., 48, 1215, 10.1016/j.yjmcc.2009.12.021 · DOI
  73. Lian, 2007, Derivation of clinically compliant MSCs from CD105+, CD24− differentiated human ESCs, Stem Cells, 25, 425, 10.1634/stemcells.2006-0420 · DOI
  74. Bernardo, 2012, Mesenchymal stromal cell therapy: a revolution in regenerative medicine?, Bone Marrow Transplant., 47, 164, 10.1038/bmt.2011.81 · DOI
  75. Salem, 2010, Mesenchymal stromal cells: current understanding and clinical status, Stem Cells, 28, 585, 10.1002/stem.269 · DOI
  76. Abdallah, 2008, Human mesenchymal stem cells: from basic biology to clinical applications, Gene Ther., 15, 109, 10.1038/sj.gt.3303067 · DOI
  77. Lee, 2004, Characterization and expression analysis of mesenchymal stem cells from human bone marrow and adipose tissue, Cell. Physiol. Biochem., 14, 311, 10.1159/000080341 · DOI
  78. Giordano, 2007, From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells, J. Cell. Physiol., 211, 27, 10.1002/jcp.20959 · DOI
  79. Le Blanc, 2005, Mesenchymal stem cells: progress toward promise, Cytotherapy, 7, 36, 10.1016/S1465-3249(05)70787-8 · DOI
  80. Ankrum, 2010, Mesenchymal stem cell therapy: two steps forward, one step back, Trends Mol. Med., 16, 203, 10.1016/j.molmed.2010.02.005 · DOI
  81. Hare, 2009, A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction, J. Am. Coll. Cardiol., 54, 2277, 10.1016/j.jacc.2009.06.055 · DOI
  82. Le Blanc, 2008, Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study, Lancet, 371, 1579, 10.1016/S0140-6736(08)60690-X · DOI
  83. Duijvestein, 2010, Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study, Gut, 59, 1662, 10.1136/gut.2010.215152 · DOI · Paper page
  84. Wright, 2011, Concise review: bone marrow for the treatment of spinal cord injury: mechanisms and clinical applications, Stem Cells, 29, 169, 10.1002/stem.570 · DOI
  85. Bhansali, 2009, Efficacy of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus, Stem Cells Dev., 18, 1407, 10.1089/scd.2009.0164 · DOI
  86. Phinney, 2007, Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair — current views, Stem Cells, 25, 2896, 10.1634/stemcells.2007-0637 · DOI
  87. Iso, 2007, Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment, Biochem. Biophys. Res. Commun., 354, 700, 10.1016/j.bbrc.2007.01.045 · DOI
  88. da Silva Meirelles, 2008, In search of the in vivo identity of mesenchymal stem cells, Stem Cells, 26, 2287, 10.1634/stemcells.2007-1122 · DOI · Paper page
  89. Dai, 2005, Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium: short- and long-term effects, Circulation, 112, 214, 10.1161/CIRCULATIONAHA.104.527937 · DOI
  90. Noiseux, 2006, Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation, Mol. Ther., 14, 840, 10.1016/j.ymthe.2006.05.016 · DOI
  91. Katsha, 2011, Paracrine factors of multipotent stromal cells ameliorate lung injury in an elastase-induced emphysema model, Mol. Ther., 19, 196, 10.1038/mt.2010.192 · DOI
  92. Horwitz, 2002, Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone, Proc. Natl. Acad. Sci. U. S. A., 99, 8932, 10.1073/pnas.132252399 · DOI · Paper page
  93. Toma, 2002, Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart, Circulation, 105, 93, 10.1161/hc0102.101442 · DOI
  94. Caplan, 2006, Mesenchymal stem cells as trophic mediators, J. Cell. Biochem., 98, 1076, 10.1002/jcb.20886 · DOI · Paper page
  95. Gnecchi, 2006, Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement, FASEB J., 20, 661, 10.1096/fj.05-5211com · DOI
  96. Timmers, 2008, Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium, Stem Cell Res., 1, 129, 10.1016/j.scr.2008.02.002 · DOI
  97. Togel, 2005, Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms, Am. J. Physiol. Renal Physiol., 289, F31, 10.1152/ajprenal.00007.2005 · DOI
  98. Arthur, 2009, The therapeutic applications of multipotential mesenchymal/stromal stem cells in skeletal tissue repair, J. Cell. Physiol., 218, 237, 10.1002/jcp.21592 · DOI
  99. Humphreys, 2008, Mesenchymal stem cells in acute kidney injury, Annu. Rev. Med., 59, 311, 10.1146/annurev.med.59.061506.154239 · DOI
  100. Patel, 2007, Mesenchymal stem cells attenuate hypoxic pulmonary vasoconstriction by a paracrine mechanism, J. Surg. Res., 143, 281, 10.1016/j.jss.2006.11.006 · DOI
  101. Timmers, 2011, Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction, Stem Cell Res., 6, 206, 10.1016/j.scr.2011.01.001 · DOI
  102. Marigo, 2011, The immunomodulatory properties of mesenchymal stem cells, Semin. Immunopathol., 33, 593, 10.1007/s00281-011-0267-7 · DOI
  103. Potian, 2003, Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens, J. Immunol., 171, 3426, 10.4049/jimmunol.171.7.3426 · DOI
  104. Tse, 2003, Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation, Transplantation, 75, 389, 10.1097/01.TP.0000045055.63901.A9 · DOI
  105. Bartholomew, 2002, Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo, Exp. Hematol., 30, 42, 10.1016/S0301-472X(01)00769-X · DOI
  106. Di Nicola, 2002, Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli, Blood, 99, 3838, 10.1182/blood.V99.10.3838 · DOI · Paper page
  107. Le Blanc, 2003, Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex, Scand. J. Immunol., 57, 11, 10.1046/j.1365-3083.2003.01176.x · DOI
  108. Corcione, 2006, Human mesenchymal stem cells modulate B-cell functions, Blood, 107, 367, 10.1182/blood-2005-07-2657 · DOI · Paper page
  109. Chen, 2011, Enabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization of human ESC-derived MSCs, J. Transl. Med., 9, 47, 10.1186/1479-5876-9-47 · DOI
  110. Li, 2009, Generating mESC-derived insulin-producing cell lines through an intermediate lineage-restricted progenitor line, Stem Cell Res., 2, 41, 10.1016/j.scr.2008.07.006 · DOI

Cited by

Sorted by citations

See all 746

Metadata

Authors
Yeo, R. W. Y., Lai, R. C., Zhang, B., Tan, S. S., Yin, Y., Teh, B. J., & Lim, S. K.
Venue
Advanced Drug Delivery Reviews
Publisher
Elsevier BV
Published
2013-03
Volume
65
Issue
3
Pages
336-341
ISSN
0169-409X
DOI
10.1016/j.addr.2012.07.001
Cited by
746
References
9
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review